A phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome

Abstract WT4869 is a synthetic peptide vaccine derived from the Wilms’ tumor gene 1 (WT1) protein. This phase 1/2 open‐label study evaluated the safety and efficacy of WT4869, and biomarkers for response, in patients with myelodysplastic syndrome. WT4869 (5–1200 μg/dose) was administered intradermally every 2 weeks, according to a 3+3 dose‐escalation method in higher‐risk (International Prognostic Scoring System score ≥1.5) or lower‐risk (score
Source: Cancer Science - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research

Related Links:

In this study, we use ChIP-Seq to identify Dppa4 binding genome-wide in three distinct cell types: mouse embryonic stem cells (mESC), embryonal carcinoma cells, and 3T3 fibroblasts ectopically expressing Dppa4. We find a core set of Dppa4 binding sites shared across cell types, and also a substantial number of sites unique to each cell type. Across cell types Dppa4 shows a preference for binding to regions with active chromatin signatures, and can influence chromatin modifications at target genes. In 3T3 fibroblasts with enforced Dppa4 expression, Dppa4 represses the cell cycle inhibitor Cdkn2c and activates Ets family tra...
Source: Stem Cell Research - Category: Stem Cells Source Type: research
Conclusions: LUCAT1 was upregulated in ccRCC tissues and renal cancer cell lines, and significantly correlated with malignant stage and poor prognosis in ccRCC. LUCAT1 promoted proliferation and invasion in ccRCC cells through the AKT/GSK-3 β signaling pathway. We also revealed that LUCAT1 overexpression was induced by chemokine CXCL2. These findings indicate that the CXCL2/LUCAT1/AKT/GSK-3β axis is a potential therapeutic target and molecular biomarker for ccRCC.Cell Physiol Biochem 2018;48:891 –904
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Conclusion: Our results have revealed a novel mechanism by which ALKBH5 inhibits pancreatic cancer motility by demethylating lncRNA KCNK15-AS1, identifying a potential therapeutic target for pancreatic cancer.Cell Physiol Biochem 2018;48:838 –846
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Conclusion: Lower expression of miR-374a is associated with poor prognosis and miR-374a improves tumor biological behavior in bladder cancer cells, suggesting that miR-374a might be a novel small-molecule therapeutic target.Cell Physiol Biochem 2018;48:815 –826
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Conclusions: Our data revealbiological and functional interactions between immunotherapy and radiotherapy through the miR-195/-16 family regulatory cascade.Cell Physiol Biochem 2018;48:801 –814
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Publication date: November 2018Source: Clinica Chimica Acta, Volume 486Author(s): Jieli Li, Jing Ma, Elizabeth A. Wagar, Dong Liang, Qing H. MengAbstractBackgroundVoriconazole (VOR), an antifungal agent, is clinically monitored to guide therapeutic dosing and avoid toxicity. It is believed that measurement of serum unbound VOR provides more accurate information, especially in hypoalbuminemia patients. We developed and validated an accurate, simple and fast test with ultrafiltration and ultra-performance liquid chromatography (UPLC)-tandem mass spectrometry (MS/MS) to measure unbound VOR in human serum.MethodsThe Agilent UP...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
We present a modification of a partial sleeve left lower lobe resection in which we preserve the left upper bronchus artery by leaving the dorsal wall between the main and the left upper lobe bronchus intact thus maintaining a physiologic vascularization to the anastomosis.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
ConclusionsWe were unable to predict lung cancer recurrence using a risk-prediction model based on five well-known clinical risk-factors and several biomarkers. Further research should consider novel predictors of recurrence in order to stratify patients with completely resected early-stage NSCLC according to their risk of recurrence.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
WT4869 is a synthetic peptide vaccine derived from the Wilms’ tumor gene 1 (WT1) protein. This phase 1/2 open‐label study evaluated the safety and efficacy of WT4869, and biomarkers for response, in patients with myelodysplastic syndrome. WT4869 (5–1200 μg/dose) was administered intradermally every 2 weeks, according to a 3 + 3 dose‐escalation method in higher‐risk (International Prognostic Scoring System score ≥1.5) or lower‐risk (score
Source: Cancer Science - Category: Cancer & Oncology Authors: Tags: Original Article Source Type: research
Background: Myelodysplastic Syndrome (MDS) is a disorder of the bone marrow wherein hematopoietic cells fail to develop and differentiate into their mature forms. High iron stores in the body are known to have a detrimental effect on the overall outcome for the patient, however its exact role in the disease spectrum is currently unknown. We sought out to elucidate the role of Serum Ferritin against two end points - infection and death.Methods: The patient data was queried from METEOR (Methodist Environment for Translational Enhancement and Outcomes Research), a clinical data warehouse and analytics environment. We obtained...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Clinical Research (Excluding Clinical Trials) Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Genetics | Myelodysplastic Syndrome | Pneomococcal Vaccine | Pneumonia | Science | Study | Toxicology | Vaccines